Research progress of CD73/NT5E in glioblastoma
10.3969/j.issn.1006-5725.2024.03.026
- VernacularTitle:CD73/NT5E在胶质母细胞瘤中的研究进展
- Author:
Jiang SHAO
1
;
Lin LI
;
Yansong GUO
;
Chengyuan SUN
;
Xichao WEN
;
Kebin ZHENG
;
Yanfang SHI
Author Information
1. 河北大学附属医院神经外科 (河北保定 071000)
- Keywords:
Glioblastoma;
CD73/NT5E;
adenosine;
immune checkpoint;
immunotherapy
- From:
The Journal of Practical Medicine
2024;40(3):428-431,438
- CountryChina
- Language:Chinese
-
Abstract:
Glioma is the most common primary central nervous system tumor,mainly derived from glial cells,with strong invasiveness,easy recurrence,and poor prognosis.Glioblastoma is a high-grade glioma with the highest degree of malignancy.The clinical treatment method is mainly surgical resection,supplemented by compre-hensive treatment such as radiotherapy,chemotherapy,and electric field therapy,but the treatment effect is not satisfactory.In recent years,with the rapid development of the field of tumor immunotherapy,CD73 is a novel immune checkpoint related to adenosine metabolism,which can promote tumor progression by inhibiting anti-tumor immune responses and promoting angiogenesis.This article systematically reviews the mechanism of action of CD73 and discusses its biological role and application in glioma,aiming to provide potential treatment options for glioma patients.
